Pilot Study on Evaluating Multiparametric MRI (mp-MRI) Including Contrast-Enhanced Susceptibility Imaging (CE-SWI) in Predicting Pathology Treatment Response in Rhabdomyosarcoma

Main Article Content

Raul Valenzuela
Elvis Duran-Sierra
Mathew Antony
Sam LH Lo
Behrang Amini
Keila E Torres
Dejka Araujo
Robert S Benjamin
Jingfei Ma
Ken P Hwang
R Jason Stafford
Chengyue Wu
John E Madewell
Jossue V Espinoza
William A Murphy
Alfonso Cueto
Pia V Valenzuela
Charles Miranda-Zarate
Colleen M Costelloe

Abstract

Background and purpose: Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in the pediatric population and an aggressive cancer subtyped as embryonal, alveolar, pleomorphic, or not otherwise specified (NOS). It demonstrates post-therapeutic hemosiderin deposition, granulation tissue formation, fibrosis, and calcification. This pilot study aims to provide initial evidence for developing a multiparametric MRI-feature-derived (mp-MRI) predictive response model to outperform RECIST.
Methods: A UT MD Anderson Cancer Center IRB-approved retrospective pilot study of 11 extremity and pelvic RMS patients with presurgical mp-MRI, including diffusion-weighted imaging (DWI), contrast-enhanced susceptibility-weighted imaging (CE-SWI), and perfusion-weighted imaging with dynamic-contrast-enhancement (PWI/DCE), with surgical resection between 02/2021-06/2024. Lesions were categorized into 6 CE-SWI and 6 PWI/DCE morphologic patterns. Time-intensity curves (TICs) were classified as types I-V. Patients were categorized by the percentage of pathology-assessed treatment effect (PATE) in the surgical specimen as responders (PATE> 90%, n = 3) and partial/non-responders (PATE < 90%, n = 8).
Results: The ADC-mean for the 6 extremity RMS increased minimally from 1,425 ± 476 x 10-6 mm2/s at baseline (BL) to 1,494 ± 386 x 10-6 mm2/s at the presurgical time point (PS). The ADC-mean for the 5 pelvic RMS increased from 1,093 ± 342 x 10-6 mm2/s at BL to 1,677 ± 313 x 10-6 mm2/s at PS. All responders and partial/non-responders presented presurgical RECIST, WHO, and volume stability. At PS, 50% of responders displayed CE-SWI Complete Ring pattern (p = 0.5578), PWI/DCE Capsular pattern (p = 0.6065), and TIC Type-2 (p = 0.6065). No statistically significant differences were observed at PS in ADC or CE-SWI first- or high-order radiomics and PWI/DCE semi-quantitative parameters comparing responders vs. partial/non-responders at PS. PS ROC Analysis: The model based on the CE-SWI textural radiomic GLSZM Large-Area-High-Gray-Level-Emphasis yielded perfect classification performance (AUC = 1.0) separating responders vs. partial/non-responders, outperforming other radiomic, morphologic, and qualitative features such as ADC-Maximum-2D-Diameter-Slice (0.83), CE-SWI Complete Ring (AUC = 0.67), PWI/DCE Capsular (0.67), RECIST (0.67), and TIC type-2 (0.6).
Conclusion: Our pilot study provides initial evidence supporting a model utilizing a single CE-SWI-derived high-order texture GLSZM radiomic feature that, in our small sample, obtained a perfect classification performance (AUC = 1.0), further building on the body of evidence supporting the use of mp-MRI with CE-SWI in soft-tissue sarcoma response assessment and suggesting its potential in predicting RMS response, outperforming RECIST (AUC = 0.67). These promising early results are hindered by a limited statistical power (10%) inherent to the small sample size and the retrospective nature of an exploratory pilot study, highlighting the necessity for further validation through a larger, more representative, and balanced prospective study.

Article Details

Valenzuela, R., Duran-Sierra, E., Antony, M., Lo, S. L., Amini, B., Torres, K. E., … Costelloe, C. M. (2025). Pilot Study on Evaluating Multiparametric MRI (mp-MRI) Including Contrast-Enhanced Susceptibility Imaging (CE-SWI) in Predicting Pathology Treatment Response in Rhabdomyosarcoma. Journal of Radiology and Oncology, 062–074. https://doi.org/10.29328/journal.jro.1001083
Research Articles

Copyright (c) 2025 Valenzuela RF, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

1. Saboo SS, Krajewski KM, Zukotynski K, Howard S, Jagannathan JP, Hornick JL, et al. Imaging features of primary and secondary adult rhabdomyosarcoma. Am J Roentgenol. 2012;199(6):W694–W703. Available from: https://doi.org/10.2214/ajr.11.8213

2. Wardelmann E, Haas RL, Bovée JV, Terrier P, Lazar A, Messiou C, et al. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas: the European Organization for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC–STBSG) recommendations for pathological examination and reporting. Eur J Cancer. 2016;53:84–95. Available from: https://doi.org/10.1016/j.ejca.2015.09.021

3. Soldatos T, Ahlawat S, Montgomery E, Chalian M, Jacobs MA, Fayad LM. Multiparametric assessment of treatment response in high-grade soft-tissue sarcomas with anatomic and functional MR imaging sequences. Radiology. 2016;278(3):831–840. Available from: https://doi.org/10.1148/radiol.2015142463

4. Tsagozis P, Brosjö O, Skorpil M. Preoperative radiotherapy of soft-tissue sarcomas: surgical and radiologic parameters associated with local control and survival. Clin Sarcoma Res. 2018;8:1–7. Available from: https://doi.org/10.1186/s13569-018-0106-x

5. Rosenberg AR, Anderson JR, Lyden E, Rodeberg DA, Wolden SL, Kao SC, et al. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children’s Oncology Group. Eur J Cancer. 2014;50(4):816–823. Available from: https://doi.org/10.1016/j.ejca.2013.11.031

6. Nakazawa MS, Livingston JA, Zarzour MA, Bishop AJ, Ratan R, Ludwig JA, et al. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: a single-institution cohort. Rare Tumors. 2024;16. Available from: https://doi.org/10.1177/20363613241271669

7. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC; 2013. p. 201–213. Available from: https://doi.org/10.1097/pat.0000000000000050

8. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica. 2021;113(2):70. Available from: https://doi.org/10.32074/1591-951x-213

9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. Available from: https://doi.org/10.1016/j.ejca.2008.10.026

10. Crago AM, Cardona K, Koseła-Paterczyk H, Rutkowski P. Management of myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Surg Oncol Clin N Am. 2022;31(3):419–430. Available from: https://doi.org/10.1016/j.soc.2022.03.006

11. Subhawong TK, Wilky BA. Value added: functional MR imaging in management of bone and soft tissue sarcomas. Curr Opin Oncol. 2015;27(4):323–331. Available from: https://doi.org/10.1097/cco.0000000000000199

12. Haacke EM, Reichenbach JR. Susceptibility weighted imaging in MRI: basic concepts and clinical applications. Hoboken: John Wiley & Sons; 2014. Available from: https://onlinelibrary.wiley.com/doi/book/10.1002/9780470905203

13. Valenzuela RF, Madewell JE, Kundra V, Costelloe CM. Advanced imaging in musculoskeletal oncology: moving away from RECIST and embracing advanced bone and soft tissue tumor imaging (ABASTI) – Part I: tumor response criteria and established functional imaging techniques. Semin Ultrasound CT MR. 2021;42(1):3–12. Available from: https://doi.org/10.1053/j.sult.2020.08.013

14. Valenzuela RF, Amini B, Duran-Sierra E, Canjirathinkal MA, Madewell JE, Costelloe CM, et al. Multiparametric MRI for the assessment of treatment effect and tumor recurrence in soft-tissue sarcoma of the extremities. J Radiol Oncol. 2023;7(3):58–65. Available from: https://www.radiooncologyjournal.com/index.php/jro/article/view/jro-aid1055

15. Sierra ED, Valenzuela R, Canjirathinkal MA, Costelloe CM, Moradi H, Madewell JE, et al. Cancer radiomic and perfusion imaging automated framework: validation on musculoskeletal tumors. JCO Clin Cancer Inform. 2024;8:e2300118. Available from: https://doi.org/10.1200/cci.23.00118

16. Subhawong TK, Feister K, Sweet K, Alperin N, Kwon D, Rosenberg A, et al. MRI volumetrics and image texture analysis in assessing systemic treatment response in extra-abdominal desmoid fibromatosis. Radiol Imaging Cancer. 2021;3(4):e210016. Available from: https://doi.org/10.1148/rycan.2021210016

17. Valenzuela R, Duran-Sierra E, Canjirathinkal M, Amini B, Torres KE, Benjamin RS, et al. Perfusion-weighted imaging with dynamic contrast enhancement (PWI/DCE) morphologic, qualitative, semiquantitative, and radiomics features predicting undifferentiated pleomorphic sarcoma (UPS) treatment response. Sci Rep. 2024;14(1):21681. Available from: https://doi.org/10.1038/s41598-024-72780-7

18. Valenzuela RF, Amini B, Duran-Sierra E, Canjirathinkal M, Idrees H, Madewell J, Costelloe C, Murphy W. Susceptibility-weighted imaging (SWI) in benign and malignant tumors of the musculoskeletal system. Eur Congr Radiol. 2023. Available from: https://epos.myesr.org/poster/esr/ecr2023/C-19005

19. Valenzuela RF, Duran-Sierra EJ, Canjirathinkal MA, Amini B, Hwang KP, Ma J, et al. Novel use and value of contrast-enhanced susceptibility-weighted imaging morphologic and radiomic features in predicting extremity soft tissue undifferentiated pleomorphic sarcoma treatment response. JCO Clin Cancer Inform. 2025;9:e2400042. Available from: https://doi.org/10.1200/cci.24.00042

20. Norman G, Fayter D, Lewis-Light K, McHugh K, Levine D, Phillips B, et al. Mind the gap: extent of use of diffusion-weighted MRI in children with rhabdomyosarcoma. Pediatr Radiol. 2015;45:778–781. Available from: https://doi.org/10.1007/s00247-014-3120-z

21. Kralik SF, Haider KM, Lobo RR, Supakul N, Calloni SF, Soares BP. Orbital infantile hemangioma and rhabdomyosarcoma in children: differentiation using diffusion-weighted magnetic resonance imaging. J AAPOS. 2018;22(1):27–31. Available from: https://doi.org/10.1016/j.jaapos.2017.09.002

22. Valenzuela R, Duran-Sierra E, Canjirathinkal M, Amini B, Torres KE, Benjamin RS, et al. Radiomics by quantitative diffusion-weighted MRI for predicting response in patients with extremity soft-tissue undifferentiated pleomorphic sarcoma. J Radiol Oncol. 2024;8(2):64–71. Available from: https://doi.org/10.29328/journal.jro.1001066

23. Chatziantoniou C, Schoot RA, van Ewijk R, van Rijn RR, Ter Horst SAJ, et al. Methodological considerations on segmenting rhabdomyosarcoma with diffusion-weighted imaging—what can we do better? Insights Imaging. 2023;14(1):19. Available from: https://doi.org/10.1186/s13244-022-01351-z

24. Inarejos Clemente EJ, Navallas M, Barber Martínez de la Torre I, Suñol M, Munuera Del Cerro J, Torner F, et al. MRI of rhabdomyosarcoma and other soft-tissue sarcomas in children. Radiographics. 2020;40(3):791–814. Available from: https://doi.org/10.1148/rg.2020190119

25. Maennlin S, Chaika M, Gassenmaier S, Grimm R, Sparber-Sauer M, Fuchs J, et al. Evaluation of functional and metabolic tumor volume using voxel-wise analysis in childhood rhabdomyosarcoma. Pediatr Radiol. 2023;53(3):438–449. Available from: https://doi.org/10.1007/s00247-022-05540-2

26. Wang X, Song L, Chong V, Wang Y, Li J, Xian J. Multiparametric MRI findings of sinonasal rhabdomyosarcoma in adults with comparison to carcinoma. J Magn Reson Imaging. 2017;45(4):998–1004. Available from: https://doi.org/10.1002/jmri.25484

27. Böker SM, Adams LC, Bender YY, Fahlenkamp UL, Wagner M, Hamm B, et al. Differentiation of predominantly osteoblastic and osteolytic spine metastases by using susceptibility-weighted MRI. Radiology. 2019;290(1):146–154. Available from: https://doi.org/10.1148/radiol.2018172727

28. Amini B, Duran-Sierra E, Madewell J, Murphy W, Costelloe C, Valenzuela RF. Advanced MRI can be used to determine percent necrosis in leiomyosarcoma. Eur Congr Radiol. 2024. Available from: https://dx.doi.org/10.26044/ecr2024/C-21238

29. Valenzuela RF, Duran-Sierra EJ, Canjirathinkal MA, Amini B, Hwang KP, Ma J, et al. Early results in the novel use of contrast-enhanced susceptibility-weighted imaging in the assessment of response and progression in desmoid fibromatosis: a pilot study in a specialized cancer institution. Tumor Discov. 2023;2(3):1414. Available from: https://accscience.com/journal/TD/2/3/10.36922/td.1414

30. Duran-Sierra E, Valenzuela RF, Canjirathinkal M, Madewell J, Murphy W, Costelloe C, Amini B. Susceptibility imaging (SWI) morphologic patterns and high-order radiomics of baseline and post-treatment advanced MRI of extremity soft-tissue undifferentiated pleomorphic sarcoma. Eur Congr Radiol. 2023. Available from: https://dx.doi.org/10.26044/ecr2023/C-19060

31. Ghadimi M, Sapra A. Magnetic resonance imaging contraindications. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. PMID: 31869133. Available from: https://pubmed.ncbi.nlm.nih.gov/31869133/

32. Melazzini L, Bortolotto C, Brizzi L, Achilli M, Basla N, D’Onorio De Meo A, Gerbasi A, Bottinelli OM, Bellazzi R, Preda L. AI for image quality and patient safety in CT and MRI. Eur Radiol Exp. 2025;9(1):28. Available from: https://doi.org/10.1186/s41747-025-00562-5